Cargando…
Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325092/ https://www.ncbi.nlm.nih.gov/pubmed/31186615 http://dx.doi.org/10.1007/s40267-018-0594-z |
| _version_ | 1783386073336905728 |
|---|---|
| author | Scott, Lesley J. |
| author_facet | Scott, Lesley J. |
| author_sort | Scott, Lesley J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6325092 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-63250922019-01-23 Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use Scott, Lesley J. Drugs Ther Perspect Correction Springer International Publishing 2018-12-27 2019 /pmc/articles/PMC6325092/ /pubmed/31186615 http://dx.doi.org/10.1007/s40267-018-0594-z Text en © Springer Nature 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| spellingShingle | Correction Scott, Lesley J. Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use |
| title | Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use |
| title_full | Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use |
| title_fullStr | Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use |
| title_full_unstemmed | Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use |
| title_short | Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use |
| title_sort | correction to: osimertinib as first-line therapy in advanced nsclc: a profile of its use |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325092/ https://www.ncbi.nlm.nih.gov/pubmed/31186615 http://dx.doi.org/10.1007/s40267-018-0594-z |
| work_keys_str_mv | AT scottlesleyj correctiontoosimertinibasfirstlinetherapyinadvancednsclcaprofileofitsuse |